Exemplis Discimus 2006, 150(1):13-23

Mauris ligula eros, condimentum vel, malesuada ac, sollicitudin in, urna.

Ken Gyylla, Lorenza Duvala, Vifi Cridmeenb, Desda Ktrameb
a Laboratory of Internal Medicine, Ord Mantell University, Yavin Republic
b Faculty of Vascular surgery, Abrion University, Geonosis Republic
1st Clinic of Radiotherapy, Raioballo Faculty Hospital, Republic of Kashyyyk

Morbi tortor est, placerat ac, commodo vel, ultricies ac, urna. Fusce elit turpis, lacinia tristique, aliquet sit amet, blandit dictum, neque. Curabitur ante augue, pretium euismod, porta eget, hendrerit at, neque. Donec sit amet sapien vel nunc malesuada rhoncus. Integer nibh ante, consectetuer nec, condimentum accumsan, facilisis nec, ipsum. Maecenas mi dolor, ultricies sit amet, tincidunt nec, condimentum sed, libero. Cras urna felis, rhoncus eu, dictum quis, blandit non, enim. Nam ante turpis, pulvinar et, gravida sit amet, adipiscing vitae, magna.

Kľúčové slová: Proin at libero, Maecenas justo, Cras sit amet leo, Sed tincidunt, Suspendisse a sem, Duis posuere

Vložený: April 4, 2006; Přijatý: May 16, 2006; Uverejnené: July 1, 2006 

Zobraziť celý článok

Referencie

  1. Dalton LK, Demerac S, Elmes BC, Loder JW, Swan JM, Teitei T. (1967) Synthesis of the tumor-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido-[4,3-b]carbazoles. Aust J Chem 20, 27152727. Prejsť k pôvodnému zdroju...
  2. .Rouesse JG, Le Chevalier T, Caille F, Mondesir JM., Sancho- Gamier H., May-Levin F Spielman M, DeJager R, Amiel JL.(1985) Phase II study of ellipticinium in advanced breast cancer. Cancer Treat Rep 69, 707708.
  3. Mathe G, Triana K, Pontiggia P, Blanquet D, Hallard M, Morette C. (1998) Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combination with other HIV1 virostatic. Biomed Pharmacother 52, 391396. Prejsť k pôvodnému zdroju...
  4. Goodwin S, Smith AF, Horning EC. (1959) Alkaloids of Ochrosia elliptica Labill. J Am Chem Soc 81, 19031908. Prejsť k pôvodnému zdroju...
  5. Auclair C. (1987) Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 259, 114. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  6. Boyd MR.(1989) Status of the NCI preclinical antitumor drug discovery screen: Implications for selection of new agents for clinical trials. In: DeVita VT Jr, Hellman S and Rosenburg S, Editors. Cancer: Principles and Practice of Oncology Updates. vol. 3, Philadelphia: Lippincott, p. 112.
  7. Boyd MR. (1993) The future of drug development. In: Niederhuber JE, Editor. Current Therapy in Oncology. Philadephia: B.C. Decker, p. 1122.
  8. Acton EM, Narayanan VL, Risbood PA, Shoemaker PH, Vistica DT, Boyd MR. (1994) Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. J Med Chem 37, 21852189. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  9. Arguello F, Alexander MA, Greene JF Jr, Stinson SF, Jorden JL, Smith EM, Kalavar NT, Alvord WG, Klabansky RL, Sausville EA. (1998) Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs to treatment of human brain tumor xenografts. J Cancer Res Clin Oncol 124, 1926. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  10. DeMarini DM, Abu-Shakra A, Gupta R, Hendee LJ, Levine JG. (1992) Molecular analysis of mutations induced by the intercalating agent ellipticine at the hisD3052 allele of Salmonella typhimurium TA98. Environ Mol Mutagenesis 20, 1218. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  11. Singh MP, Hill GC, Peoch D, Rayner B, Inabach JL, Lown JW. (1994) High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33, 1027110285. Prejsť k pôvodnému zdroju...
  12. Chu Y, Hsu MT. (1992) Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. Nucleic Acids Res 20, 40334038. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  13. Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek JJr, Fermandjian S. (1991) DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 25, 18201829.
  14. Fossé P, René B, Charra M, Paoletti C, Saucier JM. (1992) Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol 42, 590595. Prejsť na PubMed...
  15. Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB. (1995) Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 270, 149981504. Prejsť k pôvodnému zdroju...
  16. Peng Y, Li C, Chen L, Sebti S, Chen J. (2003) Rescue of mutant p53 transcription function of ellipticine. Oncogene 22, 4478 4487. Prejsť k pôvodnému zdroju...
  17. Sugikawa E, Hosoi T, Yazaki N, Gamanuma N, Nakanishi N, Ohashi M. (1999) Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res 19, 30993108.
  18. Ohashi M, Sugikawa E, Nakanishi N. (1995) Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism. Jpn J Cancer Res 86, 819829. Prejsť k pôvodnému zdroju...
  19. Kuo PL, Hsu Y, Chang C, Lin C. (2005) The mechanism of ellipticine- induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 223, 293301. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  20. Schwaller MA, Allard B, Lescot E and Moreau F. (1995) Protonophoric activity of ellipticine and isomers across the energy- transducing membrane of mitochondria. J Biol Chem 270, 2270922713. Prejsť k pôvodnému zdroju...
  21. Hagg M, Berndtsson M, Mandic A, Zhou R, Shoshan MC, Linder S. (2004) Induction of endoplasmic reticulum stress by ellipticine plant alkaloids. Mol Cancer Ther 3, 489497. Prejsť na PubMed...
  22. Stiborová M, Bieler CA, Wiessler M, Frei E. (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62, 675684. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  23. Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M. (2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64, 289295. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  24. Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E. (2003) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16, 3847. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  25. Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E. (2003) DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int J Cancer 107, 885890. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  26. Bořek-Dohalská L, Frei E, Stiborová M. (2004) DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun 69, 603615. Prejsť k pôvodnému zdroju...
  27. Stiborová M, Sejbal J, Bořek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudeček J, Wiessler M, Frei E. (2004) The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res 64, 83748380. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  28. Poljaková J, Stiborová M. (2004) Peroxidase-mediated ellipticine- DNA adduct formation explains the selective efficiency of this anticancer drug against breast cancer and leukemia. Chem Listy 98, 298.
  29. Poljaková J, Forsterová K, Šulc M, Frei E, Stiborová M. (2005) Oxidation of ellipticine by peroxidases. Biomed Papers 149, 449 453. Prejsť k pôvodnému zdroju...
  30. Stiborova M, Poljakova J, Ryslava H, Dracinsky M, Eckschlager T, Frei E. (2006) Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer, submitted.
  31. Stiborova M, Borek-Dohalska l, Aimova D, Kotrbova V, Kukackova K, Janouchova K, Rupertova M, Ryslava H, Hudecek J, Frei E. (2006) Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes similarity between human and rat systems. Gen Physiol Biophys, in press.
  32. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 41380. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  33. Stiborová M, Rupertová M, Hodek P, Frei E, Schmeiser HH. (2004) Monitoring of DNA adducts in humans and 32P-postlabelling methods. A review. Collect Czech Chem Commun 69, 477498. Prejsť k pôvodnému zdroju...
  34. Murray GI., Weaver RJ, Paterson PJ, Ewen SW, Melvin WT, Burke MD. (1993) Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol 169, 347353. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  35. Murray GI, Melvin WT, Burke M. Cytochrome P450 expression in tumors. (1995) J Pathol 176, 323324.
  36. Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S. Antitumor prodrug development using cytochrome P450 (CYP) mediated activation. Anti-Cancer Drug Design 1999;14:47386.
  37. El-Rayes BF, Ali S, Heilbrun LK, Lababidi S, Bouwman S, Vischer D, Philip PA. (2003) Cytochrome P450 and glutathione transferase expression in human breast cancer. Clin Cancer Res 9, 17051709.
  38. Rekha GK, Sladek NE. (1997) Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics. Cancer Chemother Pharmacol 40, 215224. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  39. Ivy SP, Tulpule A, Fairchild CR, Averbuch SD, Myers CE, Nebert DW, Baird WM, Cowan KH. (1988) Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J Biol Chem 263, 1911919125.
  40. Hofle G, Glase N, Leibold T, Sefkow M. Epothilone A-D and their thiazole-modified analogs as novel anticancer agents. Pure Appl Chem 1999; 71: 201924. Prejsť k pôvodnému zdroju...
  41. Nicolaou KC, Ritzén A, Namoto K. (2001) Recent developments in the chemistry, biology and medicine of the epothilones. Chem Commun 15231535.
  42. Schlaifer D, Meyer K, Muller C, Attal M, Smith MT, Tamaki S, Weimels J, Pris J, Jaffrezou JP, Laurent G, Myers CE. (1994) Antisense inhibition of myeloperoxidase increases the sensitivity of the HL-60 cell line to vincristine. Leukemia 8, 289291.
  43. Lűbbert M, Miller CW, Koeffler HP. (1991) Changes of DNA methylation and chromatin structure in the human myeloperoxidase gene during myeloid differentiation. Blood 78, 345356.
  44. Hoy A, Leininger-Muller B, Jolivalt C, Siest G. (2000) Effect of apolipoprotein E on cell viability in a human neuroblastoma cell line: influence of oxidation and lipid-association. Neurosci Lett 285, 173176 Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  45. Kirschenbaum A, Klausner AP, Lee R, Unger P., Yao S., Kiu X.H.,.Levine A.C. (2000) Expression of cyclooxygenase-1 and cyclooxygenase- 2 in the human prostate. Urology 56, 671676. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  46. Williams JA, Phillips DH. (2000) Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 60, 46674677.
  47. Soslow RA, Dannenberg AJ, Rush D, Woemer B.M., Khan KM, Masferrerer J., Koki AT. (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89, 26372645. Prejsť k pôvodnému zdroju...
  48. Matsuo M, Yonemitsu N, Zaitsu M, Ishii K, Hamasaki Y, Fukuyama K, Tabuchi K, Miyazaki S. (2001) Expression of prostaglandin H synthase-2 in human brain tumors. Acta Neuropathol 102, 181 187.
  49. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. (2001) Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 61, 43754381. Prejsť na PubMed...
  50. Peng JP, Su CY, Chang HC, Chai CY, Hung WC. (2002) Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Human Pathol 33, 100104. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  51. Castilla EA, Prayson RA, Kanner AA, Rybicky LA., Tubbs R.R., Vogelbaum M.A., Barnett G.H. (2003) Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer 8, 14651472. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  52. Ludwig-Muller J, Tokalov SV, Franz A, Gutzeit HO. (2005) Quercetin metabolism in vital and apoptotic human leukaemia cells. Biol Chem 386, 279283. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  53. Schmelz K, Sattler N, Wagner M, Lűbbert M, Dorken B, Tamm I. (2005) Induction of gene expression by 5-aza-2-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DANN-methylation-dependent and independent mechanisms. Leukemia 19, 103111. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  54. Auclair C, Dugué B, Meunier B, Paoletti C. (1986) Peroxidasecatalyzed covalent binding of the antitumor drug N2-methyl-9-hydroxyellipticinium to DNA in vitro. Biochemistry 25, 1240-1245. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  55. Dugué B, Auclair C, Meunier B. (1986) Covalent binding of elliptinium acetate (NSC 264137) to nucleic acids of L1210 cells in culture. Cancer Res 46, 38283833. Prejsť na PubMed...
  56. Dugue B, Paoletti C, Meunier B. (1984) Covalent binding of antitumor agent N2-methyl-9-hydroxy-ellipticinium acetate (NSC 264137) on RNA and poly A in vitro. Biochem Biophys Res Commun 124, 416422. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  57. Bernadou J, Meunier G, Paoletti C, Meunier B. (1983) Orthoquinone formation in the biochemical oxidation of the anti-tumor drug N2-methyl-9-hydroxyellipticinium acetate. J Med Chem 26, 574579. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  58. Meunier G, Meunier B. (1985) Peroxidase-catalyzed O-demethylation reactions quinone-imine fromation from 9-methoxyellipticine derivatives. J Biol Chem 260, 1057610582.
  59. Meunier G, Demontauzon D, Bernandou J, Grassy G, Bonnafous M, Cros S, Meunier B. (1988) The biooxidation of cyto-toxic ellipticine derivatives a key to structure-activity relationship studies. Mol Pharmacol 33, 93102. Prejsť na PubMed...
  60. Bernadou J, Bonnafous M, Labat G, Loiseau P, Meunier B. (1991) Model systems for metabolism studies biomimetic oxidation of acetaminophen and ellipticine derivatives with water-soluble metalloporphyrins associated to potassium monopersulfate. Drug Metab Dispos 19, 360365. Prejsť na PubMed...
  61. Pratviel G, Bernadou J, Ha T, Meunier G, Cros S., Meunier B, Gillet B, Guitret E. (1986) Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(t)ides biological-activities of the resulting adducts. J Med Chem 20, 13501355. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  62. Kansal VK, Funakoshi S, Mangeney P, Gillet B, Guittet E, Lallemand JY, Potier P. (1985) Interaction of nucleosides with antitumoral agents 9-hydroxy-N2-methylellipticinium acetate and 9-hydroxy-N2-methylolivacinium acetate. Tetrahedron 41, 5107 5120. Prejsť k pôvodnému zdroju...
  63. Kansal VK, Potier P, Gillet B, Guittet E, Lallemand J-Y, Huynh- Dinh T, Igolen J. (1985) Regioselective and stereoselective alkylation at the 3-terminal end of ribonucleotides by N2-methyl- 9-hydroxyellipticinium acetate an antitumor agent. Tetrahedron Lett 26, 28912894. Prejsť k pôvodnému zdroju...
  64. Donaghy MJ, Stanforch SP. (1999) Nucleophilic addition of fused benzimidazole N-oxide. Tetrahedron 55, 14411448. Prejsť k pôvodnému zdroju...
  65. Josephy PD. (1996) The role of peroxidase-catalyzed activation of aromatic amines in breast cancer. Mutagenesis 11, 37. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  66. Gorlewska-Roberts KM, Teitel CH, Lay JO, Roberts DW, Kadlubar FF. (2004) Lactoperoxidase-catalyzed activation of carcinogenic aromatic and heterocyclic amines. Chem Res Toxicol 17, 1659 1666. Prejsť k pôvodnému zdroju...
  67. Yha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215, 120.
  68. Noguchi N, Nakano K, Aratani Y, Koyama H, Kodama T, Niki E. J. (2000) The role of myeloperoxidase in neutrophil-induced oxidation of low density lipoprotein as studied by myeloperoxidaseknockout mouse. Biochem. (Tokyo) 127, 971977. Prejsť k pôvodnému zdroju... Prejsť na PubMed...

Späť na obsah